Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Shahim, Bahira
Shahim, Angiza
Adamo, Marianna
Chioncel, Ovidiu
Benson, Lina
Anker, Stefan
Coats, Andrew J.S.
Filippatos, Gerasimos
Lainscak, Mitja

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Shahim B, Shahim A, Adamo M, Chioncel O, Benson L, Crespo-Leiro MG, Anker SD, Coats AJS, Filippatos G, Lainscak M, McDonagh T, Mebazaa A, Piepoli MF, Rosano GMC, Ruschitzka F, Savarese G, Seferovic P, Volterrani M, Crespo Leiro M, Segovia Cubero J, Amir O, Palic B, Maggioni AP, Metra M, Lund LH. Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2023 Jul;25(7):1049-1060.

Type of academic work

Academic degree

Abstract

[Abstract] Aims: To assess the prevalence, clinical characteristics, and outcomes of patients with heart failure (HF) with or without moderate to severe aortic valve disease (AVD) (aortic stenosis [AS], aortic regurgitation [AR], mixed AVD [MAVD]). Methods and results: Data from the prospective ESC HFA EORP HF Long-Term Registry including both chronic and acute HF were analysed. Of 15 216 patients with HF (62.5% with reduced ejection fraction, HFrEF; 14.0% with mildly reduced ejection fraction, HFmrEF; 23.5% with preserved ejection fraction, HFpEF), 706 patients (4.6%) had AR, 648 (4.3%) AS and 234 (1.5%) MAVD. The prevalence of AS, AR and MAVD was 6%, 8%, and 3% in HFpEF, 6%, 3%, and 2% in HFmrEF and 4%, 3%, and 1% in HFrEF. The strongest associations were observed for age and HFpEF with AS, and for left ventricular end-diastolic diameter with AR. AS (adjusted hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.23-1.67), and MAVD (adjusted HR 1.37, 95% CI 1.07-1.74) but not AR (adjusted HR 1.13, 95% CI 0.96-1.33) were independently associated with the 12-month composite outcome of cardiovascular death and HF hospitalization. The associations between AS and the composite outcome were observed regardless of ejection fraction category. Conclusions: In the ESC HFA EORP HF Long-Term Registry, one in 10 patients with HF had AVD, with AS and MAVD being especially common in HFpEF and AR being similarly distributed across all ejection fraction categories. AS and MAVD, but not AR, were independently associated with increased risk of in-hospital mortality and 12-month composite outcome, regardless of ejection fraction category.

Description

Rights

Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC 4.0)
Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC 4.0)

Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC 4.0)